Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration

International Archives of Allergy and Immunology

Volumn 161, Issue SUPPL.1, 2013, Pages 3-9

  Cicardi, M ^a   Craig, T J ^b   Martinez Saguer, I ^c   Hebert J ^d   Longhurst, H J ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITÉ LAVAL   (Canada)

^e BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

Consensus; Guidelines; Hereditary angioedema; Self administration

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ICATIBANT; COMPLEMENT COMPONENT C1S;

ANGIONEUROTIC EDEMA; DISEASE DURATION; DISEASE SEVERITY; DRUG SAFETY; EMERGENCY CARE; GENERAL PRACTITIONER; LARYNX EDEMA; PATIENT SAFETY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; ADOLESCENT; CHILD; CONSENSUS DEVELOPMENT; DRUG SELF ADMINISTRATION; HOME CARE; HUMAN; MEDICATION COMPLIANCE; PATIENT COMPLIANCE;

ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INACTIVATOR PROTEINS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; GUIDELINES AS TOPIC; HUMANS; PATIENT COMPLIANCE; SELF ADMINISTRATION;

EID: 84877975489     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000351232     Document Type: Review

References (49)

1. Bowen T, Hebert J, Ritchie B, Burnham J, MacSween M, Warrington R, Yang W, Issekutz A, Karitsiotis N, McCombie N, Giulivi T: Management of hereditary angioedema: a Canadian approach. Transfus Apher Sci 2003; 29: 205-214.
2. Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, Zingale L, Varga L, Martinez-Saguer I, Aygoren- Pursun E, Binkley K, Zuraw B, Davis A 3rd, Hebert J, Ritchie B, Burnham J, Castaldo A, Menendez A, Nagy I, Harmat G, Bucher C, Lacuesta G, Issekutz A, Warrington R, Yang W, Dean J, Kanani A, Stark D, McCusker C, Wagner E, Rivard GE, Leith E, Tsai E, Mac- Sween M, Lyanga J, Serushago B, Leznoff A, Waserman S, de Serres J: Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol 2004; 114: 629-637.
3. Craig T, Aygoren-Pursun E, Bork K, Bowen T, Boysen H, Farkas H, Grumach A, Katelaris CH, Lockey R, Longhurst H, Lumry W, Magerl M, Martinez-Saguer I, Ritchie B, Nast A, Pawankar R, Zuraw B, Maurer M: WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J 2012; 5: 182-199.
4. Bork K: Current management options for hereditary angioedema. Curr Allergy Asthma Rep 2012; 12: 273-280.
5. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, Fay AC, Longhurst HJ, Morrison L, Price A, Price M, Watters D: C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139: 379-394.
6. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, Bucher C, Castaldo AJ, Cicardi M, Davis AE, De Carolis C, Drouet C, Duponchel C, Farkas H, Fay K, Fekete B, Fischer B, Fontana L, Fust G, Giacomelli R, Groner A, Hack CE, Harmat G, Jakenfelds J, Juers M, Kalmar L, Kaposi PN, Karadi I, Kitzinger A, Kollar T, Kreuz W, Lakatos P, Longhurst HJ, Lopez-Trascasa M, Martinez-Saguer I, Monnier N, Nagy I, Nemeth E, Nielsen EW, Nuijens JH, O'Grady C, Pappalardo E, Penna V, Perricone C, Perricone R, Rauch U, Roche O, Rusicke E, Spath PJ, Szendei G, Takacs E, Tordai A, Truedsson L, Varga L, Visy B, Williams K, Zanichelli A, Zingale L: Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114:S51-S131.
7. Bork K, Hardt J, Schicketanz KH, Ressel N: Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 2003; 163: 1229-1235.
8. Cicardi M, Bergamaschini L, Marasini B, Boccassini G, Tucci A, Agostoni A: Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 1982; 284: 2-9.
9. Longhurst HJ, Carr S, Khair K: C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 2007; 147: 11-17.
10. Bork K, Meng G, Staubach P, Hardt J: Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005; 45: 1774- 1784.
11. Bork K, Witzke G: Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1989; 83: 677- 682.
12. Kreuz W, Fischer D, Martinez-Saguer I, Heller C, Klarmann D: C1-esterase inhibitor substitution in hereditary angioedema. Biomed Prog 1999; 12: 1-7.
13. Kreuz W, Martinez-Saguer I, Aygoren- Pursun E, Rusicke E, Klingebiel T: Individual replacement therapy (IRT) with a pasteurized C1-inhibitor concentrate compared to prophylaxis with danazol in patients with hereditary angioedema (HAE) - a prospective study. Blood 2004; 104: 1028 (abstract).
14. Levi M, Choi G, Picavet C, Hack CE: Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117: 904-908.
15. Rusicke E, Martinez-Saguer I, Aygoren- Pursun E, Kreuz W: Home treatment in patients with hereditary angioedema (HAE). J Allergy Clin Immunol 2006; 117:S180.
16. Strawczynski H, Stachewitsch A, Morgenstern G, Shaw ME: Delivery of care to hemophiliac children: home care versus hospitalization. Pediatrics 1973; 51: 986-991.
17. Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, Ritchie B, Farkas H, Varga L, Zingale LC, Binkley K, Wagner E, Adomaitis P, Brosz K, Burnham J, Warrington R, Kalicinsky C, Mace S, McCusker C, Schellenberg R, Celeste L, Hebert J, Valentine K, Poon MC, Serushago B, Neurath D, Yang W, Lacuesta G, Issekutz A, Hamed A, Kamra P, Dean J, Kanani A, Stark D, Rivard GE, Leith E, Tsai E, Waserman S, Keith PK, Page D, Marchesin S, Longhurst HJ, Kreuz W, Rusicke E, Martinez-Saguer I, Aygoren-Pursun E, Harmat G, Fust G, Li H, Bouillet L, Caballero T, Moldovan D, Spath PJ, Smith-Foltz S, Nagy I, Nielsen EW, Bucher C, Nordenfelt P, Xiang ZY: Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008; 100:S30-S40.
18. Aygoren-Pursun E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W: On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Allergy Asthma Clin Immunol 2010; 6: 21.
19. CSL Behring: CSL Behring announces completion of national marketing authorizations of Berinert ® after MRP in 23 European countries. 2011. http://www.cslbehring.com/PRelease/ Berinert-Approved.htm?tabSelections= 1255923338674¤tPage=1 (accessed 21 November 2012).
20. Food and Drug Administration: FDA approves Berinert to treat abdominal attacks, facial swelling associated with hereditary angioedema. 2009. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2009/ ucm186257.htm (accessed 21 November 2012).
21. Food and Drug Adminstration: Cinryze approval. 2008. http://www.fda.gov/ Biologics- BloodVaccines/BloodBloodProducts/ApprovedProducts/ LicensedProductsBLAs/ FractionatedPlasmaProducts/ucm150480. htm (accessed 21 November 2012).
22. ViroPharma Inc.: ViroPharma receives complete response letter for Cinryze TM supplemental biologics licence application for acute treatment of hereditary angioedema. 2009. http://ir.viropharma.com/releasedetail. cfm?ReleaseID=543136 (accessed 21 November 2012).
23. Waknine Y: FDA approves ecallantide for hereditary angioedema. 2009. http://www. medscape.com/viewarticle/713401 (accessed
24. Shire: Jerini receives European Commission approval for Firazyr (icatibant) in the treatment of HAE. 2008. http://www.shire.com/ shireplc/en/media/shirenews?year=2008 (accessed
25. Longhurst HJ, Farkas H, Craig T, Aygoren- Pursun E, Bethune C, Bjorkander J, Bork K, Bouillet L, Boysen H, Bygum A, Caballero T, Cicardi M, Dempster J, Gompels M, Gooi J, Grigoriadou S, Huffer U, Kreuz W, Levi MM, Long J, Martinez-Saguer I, Raguet M, Reshef A, Bowen T, Zuraw B: HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010; 6: 22.
26. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, Aygoeren-Pursun E, Craig T, Binkley K, Hebert J, Ritchie B, Bouillet L, Betschel S, Cogar D, Dean J, Devaraj R, Hamed A, Kamra P, Keith PK, Lacuesta G, Leith E, Lyons H, Mace S, Mako B, Neurath D, Poon MC, Rivard GE, Schellenberg R, Rowan D, Rowe A, Stark D, Sur S, Tsai E, Warrington R, Waserman S, Ameratunga R, Bernstein J, Bjorkander J, Brosz K, Brosz J, Bygum A, Caballero T, Frank M, Fust G, Harmat G, Kanani A, Kreuz W, Levi M, Li H, Martinez-Saguer I, Moldovan D, Nagy I, Nielsen EW, Nordenfelt P, Reshef A, Rusicke E, Smith-Foltz S, Spath P, Varga L, Xiang ZY: 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
27. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, Craig T, Grant JA, Hurewitz D, Bielory L, Cartwright WE, Koleilat M, Ryan W, Schaefer O, Manning M, Patel P, Bernstein JA, Friedman RA, Wilkinson R, Tanner D, Kohler G, Gunther G, Levy R, McClellan J, Redhead J, Guss D, Heyman E, Blumenstein BA, Kalfus I, Frank MM: Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-522.
28. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE: Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-827.
29. Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anne S, Bjorkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hebert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernandez Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT: Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
30. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE: Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363: 523-531.
31. Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE: EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 523-529.
32. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, Reshef A, Ritchie B, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Keinecke HO, Bernstein JA: Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-808.
33. Bowen T: Hereditary angioedema: beyond international consensus - circa December 2010 - The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture. Allergy Asthma Clin Immunol 2011; 7: 1.
34. ViroPharma Inc.: ViroPharma's Cinryze ® (C1 inhibitor [human]) granted European marketing authorization for hereditary angioedema (HAE). 2011. http://ir.viropharma. com/releasedetail.cfm?ReleaseID=585060 (accessed 21 November 2012).
35. Shire: FDA approves Shire's Firazyr (icatibant injection) for acute attacks of hereditary angioedema (HAE). 2011. http://www.shire. com/shireplc/en/media/shirenews?id=520 (accessed 21 November 2012).
36. European Commission approves self-administration label for Firazyr ® (icatibant) for the symptomatic treatment of acute hereditary angioedema attacks. 2011. http://www. pharmiweb.com/PressReleases/pressrel. asp?ROW-ID=37878#axzz2Cm0UVl3D (accessed
37. CSL Behring: CSL Behring receives European Health Authorities' approval for self-administration of Berinert ® . 2011. http://www.cslbehring. com/news-room/european-healthauthorities- approve-self-adminstration-ofberinert. htm (accessed 21 November 2012).
38. CSL Behring: CSL Behring receives FDA approval of expanded label on Berinert ® for selfadministration and treatment of acute laryngeal attacks of hereditary angioedema. 2012. http://www.cslbehring-us.com/news-room/ HAE-Berinert-Self-Administration-and-Laryngeal- Attacks (accessed 21 November 2012).
39. CSL Behring: CSL Behring receives European Health Authorities' approval of Berinert ® for short-term prophylaxis in adults and children. 2013. http://www.cslbehring.com/s1/cs/enco/ 1151517263302/news/1255931201677/ prdetail.htm (accessed 17 April 2013).
40. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B, HAWK: Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-157.
41. Kreuz W, Martinez-Saguer I, Aygoren- Pursun E, Rusicke E, Heller C, Klingebiel T: C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 2009; 49: 1987-1995.
42. Wahn V, Aberer W, Eberl W, Fasshauer M, Kuhne T, Kurnik K, Magerl M, Meyer-Olson D, Martinez-Saguer I, Spath P, Staubach- Renz P, Kreuz W: Hereditary angioedema (HAE) in children and adolescents-a consensus on therapeutic strategies. Eur J Pediatr 2012; 171: 1339-1348.
43. Tourangeau LM, Castaldo AJ, Davis DK, Koziol J, Christiansen SC, Zuraw BL: Safety and efficacy of physician-supervised selfmanaged C1 inhibitor replacement therapy. Int Arch Allergy Immunol 2012; 157: 417- 424.
44. Kreuz W, Rusicke E, Martinez-Saguer I, Aygoren- Pursun E, Heller C, Klingebiel T: Home therapy with intravenous human C1- inhibitor in children and adolescents with hereditary angioedema. Transfusion 2012; 52: 100-107.
45. Bygum A, Andersen KE, Mikkelsen CS: Selfadministration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009; 19: 147-151.
46. Farkas H, Csuka D, Zotter Z, Varga L, Borocz Z, Temesszentandrasi G, Jakab L, Karadi I: Home treatment of hereditary angioedema with icatibant administered by health care professionals. J Allergy Clin Immunol 2012; 129: 851-852.
47. Boccon-Gibod I, Bouillet L: Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 2012; 168: 303-307.
48. Riedl M: Hereditary angioedema therapies in the United States: movement toward an international treatment consensus. Clin Ther 2012; 34: 623-630.
49. Dispenza MC, Craig TJ: Discrepancies between guidelines and international practice in treatment of hereditary angioedema. Allergy Asthma Proc 2012; 33: 241-248.